United States Patent 9,364,470: Claim Scope, Lomitapide Exclusivity, and Generic Risk

US Patent 9,364,470 is a regimen patent directed to stepwise dose escalation of a specific microsomal triglyceride transfer protein inhibitor, identified from the claimed structure as lomitapide or a pharmaceutically acceptable salt, including the piperidine N-oxide. The patent does not broadly claim every use of an MTP inhibitor. It claims a particular treatment sequence for hyperlipidemia or hypercholesterolemia using three specified weight-based dose bands, followed by an optional higher maximum daily dose.

The principal commercial relevance is Juxtapid, also known as lomitapide mesylate, marketed for homozygous familial hypercholesterolemia, or HoFH. The patent is a method-of-use patent rather than a composition-of-matter patent. Its enforceability therefore depends on the prescribed and administered dosing sequence, the identity of the inhibitor, and the disease being treated.

What drug does US Patent 9,364,470 protect?

The claimed MTP inhibitor is lomitapide, including pharmaceutically acceptable salts and the piperidine N-oxide form.

Attribute	Patent relevance
Active ingredient	Lomitapide
Commercial product	Juxtapid
Common salt	Lomitapide mesylate
Drug class	Microsomal triglyceride transfer protein inhibitor
FDA indication	Homozygous familial hypercholesterolemia
Patent type	Method of treatment and dose-escalation regimen
Patent number	US 9,364,470
Issue date	June 14, 2016
Patent holder at issuance	Aegerion Pharmaceuticals, Inc.
Original developer	Bristol-Myers Squibb
Licensee and commercial developer	Aegerion Pharmaceuticals

The claims do not cover lomitapide as a chemical compound in every context. They also do not cover all MTP inhibitor treatment regimens. A competing product or process would need to satisfy the structural, disease, administration, and dosing limitations in the asserted claim.

What does claim 1 of US 9,364,470 require?

Claim 1 requires all of the following elements:

A subject suffering from hyperlipidemia or hypercholesterolemia.
Administration of an effective amount of an MTP inhibitor.
The MTP inhibitor must be the claimed lomitapide structure, a pharmaceutically acceptable salt, or the piperidine N-oxide.
Administration must include at least three stepwise, increasing dose levels.
The first dose level must be about 0.02 to about 0.059 mg/kg/day.
The first dose must be administered for about two weeks.
The second dose level must be about 0.06 to about 0.19 mg/kg/day.
The second dose must be administered for about four weeks.
The third dose level must be about 0.2 to about 0.59 mg/kg/day.
The third dose must be administered for about four weeks.

The claim is cumulative. Omitting one material limitation, such as the two-week first phase or the four-week second phase, creates a substantial non-infringement argument under literal claim construction.

What does “at least three step-wise, increasing dose levels” mean?

The phrase requires a sequence in which each dose level is higher than the preceding dose level. The claim does not stop at three stages. “At least” permits additional stages after the third dose level, provided the initial three stages satisfy the claimed ranges and durations.

The claim does not expressly require:

Oral administration.
Once-daily administration.
A particular tablet strength.
A particular body weight.
A maximum dose.
A specific percentage reduction in LDL cholesterol.
Treatment of HoFH specifically, as opposed to hyperlipidemia or hypercholesterolemia more generally.
Concomitant use of a statin, ezetimibe, or other lipid-lowering therapy.

The claim does require administration to a patient. A product label alone is not necessarily direct infringement. Liability may instead depend on induced or contributory infringement theories, including whether a generic label instructs physicians and patients to follow the patented regimen.

How does claim 2 expand the patent scope?

Claim 2 adds a maximum dose level of about 50 to about 75 mg/day.

The claim therefore covers a regimen that includes:

The three weight-based escalation stages in claim 1; and
A later maximum daily dose within the 50-to-75 mg/day range.

The claim is commercially aligned with the standard lomitapide titration strategy, which permits escalation to a 60 mg daily dose in the FDA-approved labeling. The “about” language may provide some flexibility around the endpoints, but the scope remains limited by the numerical range and the other limitations incorporated from claim 1.

Claim 2 is narrower than claim 1. A regimen that practices claim 1 but stops below 50 mg/day could avoid claim 2 while remaining exposed to claim 1.

How does the patented regimen compare with the FDA-approved Juxtapid regimen?

The FDA-approved Juxtapid labeling uses a staged escalation schedule that begins at 5 mg once daily and increases at intervals of at least two weeks. The labeled dose may be increased to 10 mg, 20 mg, 40 mg, and then 60 mg once daily, subject to tolerability and clinical judgment (FDA, 2023).

The comparison is weight-dependent because the patent uses mg/kg/day while the commercial label uses fixed mg/day doses.

FDA-labeled dose	Approximate dose at 70 kg	Relationship to patent ranges
5 mg/day	0.071 mg/kg/day	Generally above the claimed first band
10 mg/day	0.143 mg/kg/day	Within the claimed second band
20 mg/day	0.286 mg/kg/day	Within the claimed third band
40 mg/day	0.571 mg/kg/day	Near the upper end of the claimed third band
60 mg/day	0.857 mg/kg/day	Outside the third weight-based band, but within claim 2's maximum-dose range

For a heavier patient, the fixed 5 mg starting dose can fall within the first claimed band. For a lighter patient, it may not. This creates a patient-specific infringement issue. The FDA label's fixed-dose instructions and the patent's weight-based ranges are not identical, although portions of the label can overlap the claimed ranges depending on patient weight and titration timing.

The patented two-week first stage also corresponds to the FDA label's minimum interval before increasing the dose. The four-week periods for the second and third stages are more specific than the FDA label's general minimum two-week escalation interval.

What are the strongest and weakest parts of the patent claims?

Strengths of the patent estate

The claims have several features that can make them commercially meaningful:

They cover the active ingredient used in Juxtapid.
They target a clinically important tolerability problem associated with lomitapide dose escalation.
The sequence is objectively measurable through prescriptions, treatment records, and dispensing data.
The claim includes the commercially relevant 60 mg maximum dose through claim 2.
A generic label that reproduces the patented titration schedule could create induced-infringement exposure.

Claim limitations that create enforcement risk

The same specificity creates design-around and invalidity issues:

The first, second, and third dose bands are narrow.
The claim uses mg/kg/day, while the approved product label uses fixed milligram doses.
The phrase “about” may require factual construction at the boundaries.
The four-week duration for the second and third stages may not match every physician's prescribing practice.
The claim covers hyperlipidemia or hypercholesterolemia, not necessarily the narrower FDA-approved HoFH population.
The patent does not claim lomitapide's chemical composition independently.
A label that omits the patented titration sequence may reduce induced-infringement risk, although actual prescribing and promotional conduct remain relevant.
A competing MTP inhibitor would not infringe unless it falls within the claimed structural definition.

The key validity questions would include anticipation by earlier lomitapide clinical protocols, obviousness of the dose-escalation schedule, written description and enablement for the full dose ranges, and the meaning of “about” and “step-wise.”

What patents protect lomitapide and Juxtapid beyond US 9,364,470?

Lomitapide's broader patent estate has historically included several categories:

Patent category	Typical subject matter	Relevance
Composition of matter	Lomitapide and related MTP inhibitor structures	Core chemical exclusivity
Salt and solid form	Lomitapide mesylate, polymorphs, and crystalline forms	API and product protection
Formulation	Oral dosage forms, excipients, dissolution and stability	Product-level protection
Treatment methods	Dose escalation, lipid reduction, HoFH treatment	Label and prescribing protection
Manufacturing	Synthesis, intermediates, purification and salt formation	Supply-chain barriers
Regulatory exclusivity	Orphan-drug and pediatric exclusivity	Non-patent market protection

US 9,364,470 is most important in the treatment-method category. It should be analyzed together with Orange Book-listed patents for Juxtapid, any later-issued continuation or divisional patents, and the current FDA product labeling. A patent-by-patent freedom-to-operate conclusion cannot be based on US 9,364,470 alone.

What is the Orange Book status of US 9,364,470?

The Orange Book status of a method-of-use patent depends on whether the patent is listed against the approved Juxtapid labeling and whether the relevant use code corresponds to the patented regimen. FDA Orange Book listings are product-specific and can change through updates, delistings, corrections, or patent-term adjustments (FDA, 2024).

For an ANDA applicant, the practical analysis is:

ANDA certification	Relevance to this patent
Paragraph I	No patent information listed
Paragraph II	Patent has expired
Paragraph III	Applicant will wait until expiration
Paragraph IV	Applicant asserts that the patent is invalid, unenforceable, or not infringed
Section viii statement	Applicant omits a patented method of use from the label, where permitted

Because US 9,364,470 claims a treatment method, an ANDA applicant may evaluate a section viii carve-out if the approved labeling can omit the patented dosing method. That strategy is difficult if the claimed titration schedule is inseparable from safe use of the product or if the generic label continues to instruct physicians to perform the same sequence.

When does US 9,364,470 lose exclusivity?

The patent's enforceable term is determined by its statutory term, any patent-term adjustment, any patent-term extension, terminal disclaimers, and applicable regulatory exclusivities. The issue date alone does not establish the expiration date.

The patent's commercial exclusivity must be separated into four periods:

Patent protection for the claimed regimen.
Any remaining composition, formulation, or manufacturing patents.
FDA orphan-drug exclusivity for the approved HoFH indication.
FDA pediatric exclusivity, if granted.

Juxtapid received FDA approval in December 2012 for adults with HoFH. Orphan-drug exclusivity generally lasts seven years from approval for the designated indication, subject to the statutory rules governing the same indication. That period is distinct from patent protection and does not block all off-label or non-overlapping uses.

A generic applicant must therefore review the current Orange Book patent listing and FDA exclusivity records rather than relying on the 2016 patent issue date.

Which companies are challenging lomitapide exclusivity?

The principal commercial risk is from generic manufacturers seeking approval of lomitapide tablets through the ANDA pathway. Because lomitapide is a small molecule, the relevant pathway is an ANDA, not a biosimilar application.

Publicly reported generic competition has been limited compared with high-volume statins and PCSK9 therapies. The commercial opportunity is constrained by:

The small HoFH patient population.
Safety monitoring and liver-related labeling requirements.
Low patient volume relative to development cost.
Potential Orange Book patents.
The need to address a restricted-distribution and risk-management environment.
The possibility of a label carve-out that removes the patented titration instructions.

No biosimilar risk applies to Juxtapid. A biosimilar is designed for biologics. Lomitapide is a chemically synthesized small molecule, so the relevant challenge is generic substitution.

What patent litigation and settlement issues matter?

A Paragraph IV filing could trigger a Hatch-Waxman action within 45 days of notice. The litigation would likely address:

Whether the ANDA product label induces use of the claimed titration method.
Whether the fixed-dose label practices the mg/kg/day ranges across a meaningful patient population.
Whether the four-week treatment periods are mandatory or merely optional.
Whether the claims are obvious in view of earlier MTP inhibitor dose-escalation protocols.
Whether the claimed ranges are adequately supported by the specification.
Whether the patent is enforceable after any prosecution-history estoppel or inequitable-conduct allegations.

A settlement could include a delayed generic launch, a license, a permitted-use carve-out, or supply arrangements. The economic value of a settlement would depend less on the broad existence of the patent than on the probability that a generic label or ordinary prescribing practice would fall within the claims.

How strong is the patent estate for lomitapide?

US 9,364,470 is strongest as a label-linked patent. It is less powerful as a standalone barrier to all generic lomitapide sales because it does not claim the active ingredient itself and requires a precise sequence.

The overall estate can be characterized as follows:

Risk area	Assessment
Composition-of-matter protection	Potentially more significant than the asserted regimen patent, depending on current expiration
Dose-escalation patent	Commercially relevant but fact-intensive
Formulation protection	Depends on the specific listed claims and generic formulation
Manufacturing protection	Can delay or complicate API sourcing without blocking all finished-product manufacture
Biosimilar risk	None
ANDA Paragraph IV risk	Material if the patent is listed and the generic label includes the regimen
Section viii carve-out	Potentially important
Clinical-practice enforcement	Difficult because actual patient weight and treatment duration vary
Market size	Small, specialized HoFH market

What generic launch scenarios exist for Juxtapid?

Full-label generic launch

A generic applicant could challenge all relevant patents and seek approval with the full titration regimen. This creates the highest litigation exposure but gives the generic access to the complete FDA-approved market.

Carved-out-label launch

The applicant could remove the patented dose-escalation method if FDA permits a section viii statement. This may reduce induced-infringement exposure but can also impair safe-use instructions and commercial competitiveness.

At-risk launch

A generic could launch before final resolution of patent litigation after receiving approval. The risk would include damages, an injunction, and potential disruption of supply and reimbursement.

Licensed entry

The patent holder could authorize entry on a negotiated date. Such an agreement might include royalties, supply terms, or restrictions on indication and labeling.

Key Takeaways

US 9,364,470 is a lomitapide dose-escalation patent, not a broad compound patent.
Claim 1 requires three increasing weight-based dose levels and specified treatment durations.
Claim 2 adds a 50-to-75 mg/day maximum-dose limitation.
The patent overlaps with parts of the FDA-approved Juxtapid titration strategy, but the FDA label uses fixed milligram doses rather than mg/kg/day.
Infringement is likely to depend on patient weight, actual dosing, escalation timing, and duration.
The patent is more relevant to generic labeling and induced infringement than to blocking every sale of lomitapide.
Lomitapide is a small molecule, so generic ANDA challenges, not biosimilar applications, are the relevant competitive threat.
A section viii carve-out may be a significant generic-entry strategy if FDA labeling rules permit omission of the patented regimen.
The full exclusivity analysis requires review of all Orange Book-listed Juxtapid patents, continuation patents, patent-term adjustments, regulatory exclusivity, and any Paragraph IV litigation or settlement.

FAQs About US Patent 9,364,470 and Lomitapide

Does US 9,364,470 cover all lomitapide products?

No. It covers a specific method of administering lomitapide or the claimed related forms in a defined escalating regimen for hyperlipidemia or hypercholesterolemia.

Does a 60 mg lomitapide dose infringe claim 1?

Not necessarily. Claim 1 is based on three weight-adjusted dose bands. A 60 mg dose may fall outside those bands depending on patient weight and is addressed expressly by claim 2 only when the complete claim 1 sequence is also practiced.

Can a generic sell lomitapide after the patent expires?

Expiration of this patent alone may not authorize launch. The generic applicant must also address other unexpired Orange Book patents, regulatory exclusivities, formulation rights, and any litigation-related restrictions.

Is lomitapide subject to biosimilar competition?

No. Lomitapide is a small-molecule drug. Competition would proceed through the ANDA generic-drug pathway.

Can a physician infringe the patent by using the FDA-approved Juxtapid schedule?

Potentially, if the actual patient, product form, dose levels, and treatment durations satisfy every claim limitation. The FDA approval of a regimen does not itself resolve patent infringement, validity, or induced-infringement questions.

References

U.S. Patent No. 9,364,470. (2016). Methods for treating hyperlipidemia. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2023). Juxtapid (lomitapide) prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (2012). FDA approves Juxtapid to reduce cholesterol in patients with rare inherited disorder. FDA.
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355 and 35 U.S.C. §§ 156, 271.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1725234	⤷ Start Trial	CA 2014 00002	Denmark	⤷ Start Trial
European Patent Office	1725234	⤷ Start Trial	C300634	Netherlands	⤷ Start Trial
European Patent Office	1725234	⤷ Start Trial	PA2014001	Lithuania	⤷ Start Trial
European Patent Office	1725234	⤷ Start Trial	C20140001 00107	Estonia	⤷ Start Trial
European Patent Office	1725234	⤷ Start Trial	14C0003	France	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,364,470

Summary for Patent: 9,364,470